Last reviewed · How we verify

(Arm Closed) Dalteparin — Competitive Intelligence Brief

(Arm Closed) Dalteparin ((Arm Closed) Dalteparin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Low-molecular-weight heparin (LMWH). Area: Cardiovascular.

phase 3 Low-molecular-weight heparin (LMWH) Antithrombin III (indirect); Factor Xa and Thrombin (downstream targets) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

(Arm Closed) Dalteparin ((Arm Closed) Dalteparin) — University of Melbourne. Dalteparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
(Arm Closed) Dalteparin TARGET (Arm Closed) Dalteparin University of Melbourne phase 3 Low-molecular-weight heparin (LMWH) Antithrombin III (indirect); Factor Xa and Thrombin (downstream targets)
clexane (LMWH) clexane (LMWH) HaEmek Medical Center, Israel marketed Low-molecular-weight heparin (LMWH) Coagulation factors Xa and IIa (via antithrombin III enhancement)
dose adaptation of Enoxaparin dose adaptation of Enoxaparin French Cardiology Society marketed Low-molecular-weight heparin (LMWH) Factor Xa and Factor IIa (via antithrombin III enhancement)
Intermediate dose dalteparin Intermediate dose dalteparin Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) marketed Low-molecular-weight heparin (LMWH) Antithrombin III (indirect); Factor Xa and Thrombin (downstream targets)
Hepalean Heparin Hepalean Heparin McMaster University marketed Low-molecular-weight heparin (LMWH) Antithrombin III (indirect target); Factors Xa and IIa
Intermediate dose nadroparin Intermediate dose nadroparin Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) marketed Low-molecular-weight heparin (LMWH) Factor Xa, Thrombin (via antithrombin III enhancement)
innohep® innohep® LEO Pharma marketed Low-molecular-weight heparin (LMWH) Antithrombin III (enhancer); Factor Xa and Thrombin (indirect targets)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Low-molecular-weight heparin (LMWH) class)

  1. Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 7 drugs in this class
  2. University of Melbourne · 3 drugs in this class
  3. French Cardiology Society · 2 drugs in this class
  4. Ottawa Hospital Research Institute · 2 drugs in this class
  5. McMaster University · 2 drugs in this class
  6. Assistance Publique - Hôpitaux de Paris · 2 drugs in this class
  7. GlaxoSmithKline · 1 drug in this class
  8. IRCCS Azienda Ospedaliero-Universitaria di Bologna · 1 drug in this class
  9. Cristália Produtos Químicos Farmacêuticos Ltda. · 1 drug in this class
  10. Helsinki University Central Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). (Arm Closed) Dalteparin — Competitive Intelligence Brief. https://druglandscape.com/ci/arm-closed-dalteparin. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: